Sponsors (21)
The bill increases clarity, incentives, and oversight to accelerate pediatric cancer and rare-disease drug development, but it also creates risks of data gaps for combination treatments, potential review delays for non-voucher drugs, and added costs and administrative burdens for regulators and smaller sponsors.
Children with cancer will face clearer, targeted pediatric study requirements (including dosing, safety, and preliminary efficacy data) so labeling and care are better informed.
Extending the rare pediatric disease priority review voucher program through 2029 keeps a high-value incentive in place, encouraging continued development of therapies for children with rare conditions.
The bill mandates GAO and HHS studies and reporting on pediatric cancer drug development and on the voucher program, increasing oversight and producing evidence to inform future policy.
Extending and allowing use of priority review vouchers may give voucher holders priority review slots, which can delay FDA review of other non-voucher applications and slow patient access to those drugs.
The bill limits FDA authority to require pediatric investigations of combination regimens (and allows some novel combination applications to avoid pediatric requirements for up to three years), risking gaps or delays in safety and dosing data for multi‑agent treatments used in children.
Keeping the voucher incentive through 2029 could encourage firms to pursue profitable voucher strategies rather than investing in less-commercial pediatric R&D, producing uncertain public-health returns.
Based on analysis of 3 sections of legislative text.
Introduced March 11, 2025 by Markwayne Mullin · Last progress March 11, 2025
Amends FDA law to limit and clarify when the agency can require molecularly targeted pediatric cancer studies for drugs and drug combinations, lays out procedures and a timeline for FDA guidance, and delays when the new rules apply to future drug/biologic applications. Extends the rare pediatric disease priority review voucher program through September 30, 2029, changes when the priority review user fee is paid (due when the application using the voucher is submitted), and directs multiple reports and GAO studies on implementation and program effectiveness.